Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study

What Was Tested

The paper reports a study of Insulin Aspart and NPH Insulin (isophane), published as a randomized controlled trial.

Who Took Part

According to the abstract, 6323 individuals were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

A1chieve was a 24-week, international, prospective, observational, multi-centre, open-label study in individuals with T2D starting treatment with BIAsp30, insulin detemir or insulin aspart as part of routine clinical care.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Everyone knew when Insulin Aspart was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

Topics PubMed links to this paper include Africa, Northern, Asia, Biphasic Insulins, Cohort Studies, Diabetes Mellitus, Type 2, Drug Combinations and Drug Monitoring.

What This Means in Plain Language

The paper is a randomized and open-label study of Insulin Aspart and NPH Insulin (isophane) in 6323 individuals.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Diabetes research and clinical practice), a journal based in Ireland.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page.